Milestone Pharmaceuticals Inc.MIST

Milestone Pharmaceuticals Inc. has a new nasal spray called Cardamyst, and it is now approved in China. The drug, etripamil, is meant to treat paroxysmal supraventricular tachycardia (PSVT), a sudden and unpleasant racing heartbeat that can drop patients to the floor faster than you can say “vasovagal syncope.” The product page features a flag icon, a clean design, and a promise that feels a long way from the company’s March 31 quarterly filing, which shows revenue of just $238,000-roughly the cost of a single corporate retreat to Cancún. (source: Cardamyst approval notice, https://milestonepharma.com/cardamyst/; Milestone Pharmaceuticals Inc. 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_10q.htm)

Cardamyst’s approval in China is a milestone in more senses than one. Etripamil is designed to be self-administered by patients during a PSVT episode, potentially stopping the episode before paramedics arrive. That is a genuine clinical promise, yet the company’s earnings tell a different story: a net loss of $26.1 million for the quarter, an operating loss of $23.7 million, and operating cash burn of $16.1 million. The balance sheet, meanwhile, looks healthier on paper, with $184.2 million in current assets and $71.3 million in cash and equivalents, but $112.9 million of that sits in short-term investments-hardly the kind of cash you can deploy at 3 a.m. when the next PSVT episode strikes. (source: Milestone Pharmaceuticals Inc. 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_10q.htm)

The company’s March 31, 2026 filing is a masterclass in contrasts. Revenue was $238,000 for the quarter, a figure that could buy a single executive’s bonus at a regional bank and still leave change for a fancy coffee subscription. The company’s 8-K filed on June 15, 2026 confirms that net income attributable to parent was a loss of $26.1 million, with operating income a loss of $23.7 million. Research and development expense was $3.3 million, a sum that would struggle to fund a single investigator meeting in Shanghai. Inventory, net, stands at $1.8 million, up $1.2 million from the prior period, which suggests the company is building a small physical buffer in what is otherwise a virtual business. (source: Milestone Pharmaceuticals Inc. 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_10q.htm; Milestone Pharmaceuticals Inc. 8-K filed 2026-06-15, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_8k.htm)

The company’s equity incentive plan, amended in 2026, is thick with language about clinical milestones, novel products, and geographic expansion, but the actual cash runway is thinning. The plan itself is a 67-page document stuffed with aspirations, while the balance sheet shows $157.7 million in current liabilities against $36 million of shareholders’ equity. Executive compensation remains generous: David Sandoval’s employment agreement, dated January 19, 2026, guarantees a base salary of $400,000 annually, reviewed at the discretion of the board. The optics are hard to miss. (source: Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan, as Amended, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_ex10-1.htm; Employment Agreement with David Sandoval, https://www.sec.gov/Archives/edgar/data/1408443/000110465926059752/mist-20260331xex10d2.htm)

The company’s research pipeline is real, even if the spending is modest. The clinical trials page lists multiple ongoing studies testing etripamil for PSVT and other episodic cardiovascular conditions, but the March 31, 2026 filing shows research and development expense of just $3.3 million. That is less than the cost of a single Phase III trial in the United States, let alone the cost of building a commercial footprint in China. The contrast between the aspirational language on the website and the small numbers on the balance sheet is the company’s real story. (source: Clinical Trials page, https://milestonepharma.com/pipeline/clinical-trials/; Milestone Pharmaceuticals Inc. 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_10q.htm)

The company’s short-term investments total $112.9 million, parked in instruments that presumably yield less than the interest rate on the company’s liabilities. The cash and cash equivalents of $71.3 million sit alongside $1.8 million of inventory, a figure that feels less like commercial momentum and more like a small warehouse of finished goods waiting for customers that have not yet materialised. The company’s 8-K filing on June 15, 2026 confirms the losses and burn, but it does not explain how the company plans to translate approval into revenue. (source: Milestone Pharmaceuticals Inc. 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_10q.htm; Milestone Pharmaceuticals Inc. 8-K filed 2026-06-15, https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_8k.htm)

For now, the best place to track the company is the SEC EDGAR filings index, where the numbers tell the real story. The product is approved, the trials are listed, the cash is there, the losses are real, and the revenue is microscopic. The distance between the polished product story and the balance sheet is the only metric that matters right now. (source: Milestone Pharmaceuticals Inc. SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1408443)